Celcuity (NASDAQ:CELC) Sets New 52-Week High Following Analyst Upgrade

Celcuity, Inc. (NASDAQ:CELC)’s share price reached a new 52-week high during trading on Tuesday after Wolfe Research upgraded the stock to a strong-buy rating. The stock traded as high as $96.10 and last traded at $92.23, with a volume of 1621564 shares. The stock had previously closed at $92.68.

CELC has been the topic of several other reports. Needham & Company LLC set a $95.00 price target on shares of Celcuity in a research note on Monday, October 20th. Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a research note on Sunday, October 26th. Stifel Nicolaus upped their target price on Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. HC Wainwright reissued a “neutral” rating and set a $94.00 price target (up from $77.00) on shares of Celcuity in a research report on Monday. Finally, Leerink Partners boosted their target price on Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $97.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Baker BROS. Advisors LP lifted its holdings in Celcuity by 59.0% during the first quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company’s stock valued at $43,046,000 after purchasing an additional 1,579,182 shares in the last quarter. Soleus Capital Management L.P. lifted its stake in shares of Celcuity by 17.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after buying an additional 437,696 shares in the last quarter. Vanguard Group Inc. increased its stake in Celcuity by 23.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock worth $101,717,000 after buying an additional 391,262 shares in the last quarter. Eventide Asset Management LLC raised its holdings in Celcuity by 9.8% during the second quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock valued at $18,549,000 after acquiring an additional 123,774 shares during the period. Finally, Saturn V Capital Management LP lifted its position in shares of Celcuity by 8.4% in the second quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after acquiring an additional 91,843 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Celcuity Stock Up 2.9%

The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26. The company has a 50-day moving average price of $63.59 and a 200 day moving average price of $38.66. The firm has a market capitalization of $4.36 billion, a PE ratio of -25.68 and a beta of 0.72.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. Analysts forecast that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.